To determine if differences in NMT2 protein levels correlated with disease prognosis in these breast cancer patients, we performed Kaplan–Meier overall survival (OS) analysis using the clinical outcomes associated with each breast adenocarcinoma sample. The gene discussed is NMT2; the disease is breast cancer.